Glucagon-Like Peptide 1

DRUG4 trials

Sponsors

Vanderbilt University, Papworth Hospital NHS Foundation Trust, University College Dublin, Rigshospitalet, Denmark

Conditions

Diabetes Type 2Diabetic NephropathyHeart FailureHypertensionThe GLP-1-mediated Gut-kidney AxisType 2 Diabetes

Phase 1

The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

CompletedNCT02129179

Papworth Hospital NHS Foundation TrustHeart Failure

Start: 2014-06-30End: 2016-12-31Updated: 2018-04-05

Unknown Phase

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

CompletedNCT01413542

Vanderbilt UniversityDiabetes Type 2, Hypertension

Start: 2011-11-30End: 2014-07-31Updated: 2015-11-04

The Differential Effects of Diabetes Therapy on Inflammation

CompletedNCT02150707

University College DublinDiabetic Nephropathy, Type 2 Diabetes

Start: 2014-05-31End: 2015-12-31Updated: 2016-05-18

Acute Effects of GLP-1 on Renal Hemodynamics

CompletedNCT04337268

Rigshospitalet, DenmarkThe GLP-1-mediated Gut-kidney Axis

Start: 2019-04-01End: 2020-03-01Updated: 2020-04-07

Related Papers

GLP−1 Promotes Cortical and Medullary Perfusion in the Human Kidney and Maintains Renal Oxygenation During NaCl Loading

Journal of the American Heart Association2023-02-0320 citations

Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study.

2018-12-285 citations

Dipeptidyl‐Peptidase 4 Inhibition and the Vascular Effects of Glucagon‐like Peptide‐1 and Brain Natriuretic Peptide in the Human Forearm

Journal of the American Heart Association2014-08-1538 citations

Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition

Hypertension2014-02-1165 citations